Immunome to Combine with ROME Therapeutics

TL;DR

Immunome merging with ROME Therapeutics, aiming for Q1 2025 close to build a top immuno-oncology company.

AI Summary

Immunome Inc. announced on October 3, 2024, that it entered into a definitive agreement for a business combination with ROME Therapeutics Ltd. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions. This combination aims to create a leading immuno-oncology company.

Why It Matters

This business combination is expected to create a significant player in the immuno-oncology space, potentially leading to new therapeutic developments.

Risk Assessment

Risk Level: medium — The success of the business combination and the future performance of the combined entity are subject to various risks and uncertainties, including regulatory approvals and market acceptance.

Key Players & Entities

• Immunome Inc. (company) — Registrant
• ROME Therapeutics Ltd. (company) — Party to business combination
• October 3, 2024 (date) — Date of business combination agreement
• First quarter of 2025 (date) — Expected closing date

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq

Filing Documents

• tm2425596d1_8k.htm (8-K) — 28KB
• tm2425596d1_ex99-1.htm (EX-99.1) — 223KB
• 0001104659-24-106777.txt ( ) — 471KB
• immu-20241003.xsd (EX-101.SCH) — 3KB
• immu-20241003_lab.xml (EX-101.LAB) — 33KB
• immu-20241003_pre.xml (EX-101.PRE) — 22KB
• tm2425596d1_8k_htm.xml (XML) — 4KB

01

Item 8.01 Other Events. On October 3, 2024, the Compensation Committee of the Board of Directors of Immunome, Inc. (the "Company") adopted and approved the Company's 2024 Inducement Plan (the "Inducement Plan") to reserve 2,000,000 shares of the Company's common stock to be used exclusively for grants of equity awards to individuals that were not previously employees or directors of the Company (or who are returning to employment following a bona fide period of non-employment), as an inducement material to the individual's entry into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan was adopted and approved without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). In addition, the Company's Compensation Committee of the Board of Directors adopted and approved forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise for use with the Inducement Plan. The terms and conditions of the Inducement Plan are substantially similar to the Company's stockholder-approved 2020 Equity Incentive Plan. A complete copy of the Inducement Plan is filed herewith as Exhibit 99.1. The above summary of the Inducement Plan does not purport to be complete and is qualified in its entirety by reference to such exhibit.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Immunome, Inc. 2024 Inducement Plan and Forms of Stock Option Grant Notice, Option Agreement, and Notice of Exercise thereunder. 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date:October 7, 2024 Immunome, Inc. By: /s/ Max Rosett Name: Max Rosett Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR